Osteosarcoma clinical study (dogs).


BluePearl Pet Hospitals in Kansas, Michigan, Florida and Massachusetts are now enrolling dogs with osteosarcoma who have undergone amputation and chemotherapy in a study of the Canine Osteosarcoma Vaccine, Live Listeria Vector (COV-LLV), a conditionally licensed product. For participation, a dog must meet the eligibility requirements listed below.

Study eligibility.

Exclusion criteria.

Eligibility will be confirmed by reviewing the dog’s medical history, performing a physical exam, taking thoracic radiographs, and submitting routine blood and urine testing. All dogs enrolled in the study will be treated with the vaccine.

Kansas City participation.
Contact Adrienne Hagar at (913) 642-9563 for more information.

Southfield participation.
Contact Dr. Angela Kozicki at (248) 354-6640 for more information.

Tampa participation.
Contact anyone on the oncology team in Tampa at (813) 399-8944 for more information.

Waltham/NEVOG participation.
Contact Kim Cronin, DVM, DACVIM (Oncology) at (781) 684-8688 for more information.

View current clinical studies.